StockData
Perspective Therapeutics, Inc. logo

Perspective Therapeutics, Inc. (CATX) stock

CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$0.75−0.03 (-3.85%)

Close on Nov 20, 2026Market cap $86.05MP/E –Yield –

Perspective Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Perspective Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$125.23M. For fiscal 2025 it was -$113.56M. The highest annual figure on record is -$2.96M in fiscal 2011.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$113.56M–
FY2024Dec 31, 2024-$90.89M–
FY2022Jun 30, 2022-$6.42M–
FY2021Jun 30, 2021-$3.45M–
FY2020Jun 30, 2020-$3.48M–
FY2019Jun 30, 2019-$5.25M–
FY2018Jun 30, 2018-$6.73M–
FY2017Jun 30, 2017-$6.31M–
FY2016Jun 30, 2016-$5.08M–
FY2015Jun 30, 2015-$4.34M–
FY2014Jun 30, 2014-$4.59M–
FY2013Jun 30, 2013-$4.07M–
FY2012Jun 30, 2012-$3.60M–
FY2011Jun 30, 2011-$2.96M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$29.26M–
Q1 FY2026CQ1 2026Mar 31, 2026-$28.28M–
Q4 FY2025CQ4 2025Dec 31, 2025-$39.83M–
Q3 FY2025CQ3 2025Sep 30, 2025-$27.86M–
Q2 FY2025CQ2 2025Jun 30, 2025-$24.04M–
Q1 FY2025CQ1 2025Mar 31, 2025-$21.83M–
Q4 FY2024CQ4 2024Dec 31, 2024-$44.98M–
Q3 FY2024CQ3 2024Sep 30, 2024-$18.63M–
Q2 FY2024CQ2 2024Jun 30, 2024-$14.26M–
Q1 FY2024CQ1 2024Mar 31, 2024-$13.01M–
Q4 FY2022CQ2 2022Jun 30, 2022-$2.11M–
Q3 FY2022CQ1 2022Mar 31, 2022-$1.38M–
Q2 FY2022CQ4 2021Dec 31, 2021-$1.64M–
Q1 FY2022CQ3 2021Sep 30, 2021-$2.27M–
Q4 FY2021CQ2 2021Jun 30, 2021-$1.09M–
Q3 FY2021CQ1 2021Mar 31, 2021-$766.00K–
Q2 FY2021CQ4 2020Dec 31, 2020-$873.00K–
Q1 FY2021CQ3 2020Sep 30, 2020-$714.00K–
Q4 FY2020CQ2 2020Jun 30, 2020-$1.19M–
Q3 FY2020CQ1 2020Mar 31, 2020-$548.00K–
Q2 FY2020CQ4 2019Dec 31, 2019-$903.00K–
Q1 FY2020CQ3 2019Sep 30, 2019-$836.00K–
Q4 FY2019CQ2 2019Jun 30, 2019-$1.14M–
Q3 FY2019CQ1 2019Mar 31, 2019-$1.16M–
Q2 FY2019CQ4 2018Dec 31, 2018-$1.43M–
Q1 FY2019CQ3 2018Sep 30, 2018-$1.52M–
Q4 FY2018CQ2 2018Jun 30, 2018-$2.37M–
Q3 FY2018CQ1 2018Mar 31, 2018-$1.34M–
Q2 FY2018CQ4 2017Dec 31, 2017-$1.47M–
Q1 FY2018CQ3 2017Sep 30, 2017-$1.55M–
Q4 FY2017CQ2 2017Jun 30, 2017-$1.86M–
Q3 FY2017CQ1 2017Mar 31, 2017-$1.39M–
Q2 FY2017CQ4 2016Dec 31, 2016-$1.48M–
Q1 FY2017CQ3 2016Sep 30, 2016-$1.58M–
Q4 FY2016CQ2 2016Jun 30, 2016-$1.25M–
Q3 FY2016CQ1 2016Mar 31, 2016-$1.33M–
Q2 FY2016CQ4 2015Dec 31, 2015-$1.41M–
Q1 FY2016CQ3 2015Sep 30, 2015-$1.09M–
Q4 FY2015CQ2 2015Jun 30, 2015-$1.10M–
Q3 FY2015CQ1 2015Mar 31, 2015-$1.05M–

More Perspective Therapeutics figures

See a number that looks wrong?